Aglatimagene Besadenovec

Summary

Aglatimagene Besadenovec (CHEMBL3544993) is a phase-3 clinical-stage gene; indicated across 9 conditions including hepatocellular carcinoma and glioblastoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 9 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544993
Name	Aglatimagene Besadenovec
Type	Gene
Max phase	3

Also known as: Aglatimagen besadenovec, Aglatimagene besadenovec, AdV-tk, Canatak, Gliatak, Oncatak, Prostata, Pancatak, Prostatak, Virafir, AGLATIMAGENE BESADENOVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
glioblastoma	2	MONDO:0018177	EFO:0000519
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
ependymoma	1	MONDO:0016698	EFO:1000028
glioma	1	MONDO:0021042	MONDO:0100342
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
paraganglioma	1	MONDO:0000448	EFO:1000453

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	5
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01436968	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT03313596	PHASE3	UNKNOWN	Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
NCT02446093	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
NCT02768363	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
NCT04495153	PHASE2	ACTIVE_NOT_RECRUITING	CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
NCT07332000	PHASE2	RECRUITING	A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT00870181	PHASE2	COMPLETED	ADV-TK Improves Outcome of Recurrent High-Grade Glioma
NCT02202564	PHASE2	COMPLETED	Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma
NCT00634231	PHASE1	COMPLETED	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
NCT00638612	PHASE1	COMPLETED	AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
NCT00751270	PHASE1	COMPLETED	Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
NCT01997190	PHASE1	COMPLETED	Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
NCT03576612	PHASE1	COMPLETED	GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).